AVCT:LSE-Avacta Group Plc (GBX)

COMMON STOCK | Biotechnology | LSE

Last Closing Price

GBX 213.80

Change

-11.20 (-4.98)%

Market Cap

GBX 0.54B

Volume

2.67M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Avacta Group Plc offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom, North America, Asia, and rest of Europe. It operates in three segments: Diagnostics, Therapeutics, and Animal Health. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops novel cancer immunotherapies combining proprietary platforms; and provides tools and contract services to assist diagnosis of conditions in animals to enable faster treatment for veterinarians. The company has a research partnership with Moderna Therapeutics; research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein; co-development partnership agreement with Bach Biosciences LLP to develop Affimer drug conjugate therapies; drug development collaboration with LG Chem Life Sciences; a partnership with Selexis to develop cell line for clinical manufacturing, and with Tufts University School of Medicine for developing Affimer drug conjugate therapies; a collaboration with Cytiva to develop and manufacture an Affimer-based point-of-care rapid test; and a collaboration with Adeptrix to develop Affimer-based COVID-19 antigen tests. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom. Address: Thorp Arch Estate, Wetherby, United Kingdom, LS23 7FA

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
GNS:LSE Genus plc

-70.00 (-1.36%)

GBX3.32B 69.02 33.83
HCM:LSE HUTCHMED (China) Limited

+32.50 (+8.42%)

GBX3.12B 17.41 N/A
ABC:LSE Abcam plc

-8.00 (-0.58%)

GBX3.08B 247.50 93.40
OXB:LSE Oxford Biomedica plc

N/A

GBX1.07B N/A 250.84
PRTC:LSE PureTech Health plc

+6.50 (+1.84%)

GBX1.03B 256.79 28.28
ERGO:LSE Ergomed plc

+5.00 (+0.39%)

GBX0.63B 67.19 34.71
SLN:LSE Silence Therapeutics plc

-15.00 (-2.34%)

GBX0.57B N/A N/A
SNG:LSE Synairgen plc

-5.80 (-3.48%)

GBX0.33B N/A N/A
ARIX:LSE Arix Bioscience plc

-9.00 (-4.86%)

GBX0.23B 1.98 N/A
VRP:LSE Verona Pharma plc

N/A

GBX0.23B N/A N/A

ETFs Containing AVCT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 87.54% 90% A- 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 87.54% 90% A- 97% A+
Trailing 12 Months  
Capital Gain 63.21% 66% D 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 63.21% 66% D 85% B
Trailing 5 Years  
Capital Gain 110.64% 62% D- 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 110.64% 62% D- 81% B-
Average Annual (5 Year Horizon)  
Capital Gain 135.41% 95% A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 135.41% 95% A 93% A
Risk Return Profile  
Volatility (Standard Deviation) 311.29% 12% F 12% F
Risk Adjusted Return 43.50% 61% D- 63% D
Market Capitalization 0.54B 85% B 68% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 9.04 33% F 10% F
Price / Cash Flow Ratio -50.91 84% B 91% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -43.06% 37% F 13% F
Return on Invested Capital -38.49% 52% F 9% F
Return on Assets -25.21% 42% F 6% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 2.06 14% F 5% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector